Status:

COMPLETED

SpO2 Accuracy Low Saturation Validation of the OxySoftN Sensor

Lead Sponsor:

Medtronic - MITG

Conditions:

Hypoxia

Desaturation of Blood

Eligibility:

All Genders

18-50 years

Brief Summary

To compare prototype pulse oximeter saturation measurements, during normal to low saturation, to saturation measurements made by a multi-wavelength CO-oximeter, taken from arterial blood samples from ...

Detailed Description

The study utilizes a single-site, physiology laboratory (Clinimark) for non-randomized, prospective, observational studies. The goal is to enroll a minimum of ten subjects. Subjects may be of any race...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Subject must have the ability to understand and provide written informed consent
  • Adult subjects 18 to 50 years of age.
  • Subject must be willing and able to comply with study procedures and duration.
  • Subject is a non-smoker or who has not smoked within 2 days prior to the study.
  • Male or female of any race.
  • Cleared same day Health Assessment form and health screening.
  • Cleared physical exam by a licensed physician, physician assistant, or advanced practice nurse (medical exam includes 12-lead ECG, medical history and blood test to show no sickle cell disease present)
  • Successful Perfusion Index Ulnar/Ulnar+Radial Ratio test showing adequate collateral blood flow.
  • Exclusion Criteria
  • Subject is considered as being morbidly obese (defined as BMI \>39.5)
  • Compromised circulation, injury, or physical malformation of fingers, hands, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow subjects to participate if the condition is noted and would not affect the sites utilized.)
  • Females of childbearing potential, who are pregnant, who are trying to get pregnant or who have a urine test positive for pregnancy on the day of the study
  • Subjects with COHb levels \>3% as assessed by CO-Oximetry during the procedure
  • tHb \< 10 g/dl as assessed by CO-Oximetry during the procedure
  • MetHb ≥ 2% as assessed by CO-Oximetry during the procedure
  • Subjects with known respiratory conditions such as:
  • uncontrolled / severe asthma,
  • flu or influenza type infection
  • pneumonia / bronchitis,
  • shortness of breath / respiratory distress,
  • unresolved respiratory or lung surgery,
  • emphysema, COPD, lung disease
  • Subjects with known heart or cardiovascular conditions such as:
  • Hypertension: systolic \>140mmHg, or Diastolic \>90mmHg on 3 consecutive readings.
  • have had cardiovascular surgery
  • Chest pain (angina)
  • heart rhythms other than a normal sinus rhythm or
  • with respiratory sinus arrhythmia
  • previous heart attack
  • blocked artery
  • unexplained shortness of breath
  • congestive heart failure (CHF)
  • history of stroke
  • transient ischemic attack
  • carotid artery disease
  • myocardial ischemia
  • myocardial infarction
  • cardiomyopathy
  • Self-reported health conditions as identified in the Health Assessment Form
  • diabetes,
  • uncontrolled thyroid disease,
  • kidney disease / chronic renal impairment,
  • history of seizures (except childhood febrile seizures),
  • epilepsy,
  • history of unexplained syncope,
  • recent history of frequent migraine headaches,
  • recent symptomatic head injury, within the last 2 months
  • Subjects with known clotting disorders
  • history of bleeding disorders or personal history of prolonged bleeding from injury
  • history of blood clots
  • hemophilia
  • current use of blood thinner: prescription or daily use of aspirin
  • Subjects with Severe contact allergies to standard adhesives, latex or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors
  • Subjects with prior or known severe allergies to lidocaine (or similar pharmacological agents, e.g. Novocain) or heparin
  • Arterial cannulation within the last 30 days prior to study date, (this may exclude only one radial artery site. Left or right)
  • History of clinically significant complications from previous arterial cannulation.
  • A radial artery with ten or more arterial cannulations right or left, excludes that site.
  • Unwillingness or inability to remove colored nail polish or colored artificial nails other than clear from test digits.
  • Other known health condition, should be considered upon disclosure in Health Assessment form

Exclusion

    Key Trial Info

    Start Date :

    April 6 2021

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    April 9 2021

    Estimated Enrollment :

    10 Patients enrolled

    Trial Details

    Trial ID

    NCT04811963

    Start Date

    April 6 2021

    End Date

    April 9 2021

    Last Update

    May 18 2021

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Clinimark

    Louisville, Colorado, United States, 80027